The 13th Annual BIO Investor Forum to Host Over 100 Presenting Companies

  • Contact: Abigail Hirsch
  • Phone: 202-962-9230
  • Recommend
  • Tweet
  • Print
  • Email

Washington, D.C. (August 25, 2014) – The Biotechnology Industry Organization (BIO) today announced the initial list of presenting companies for the 13th Annual BIO Investor Forum. The event is an international investor forum that assembles early and established private companies as well as emerging public biotechs, along with top public and private equity investors, to explore investment trends and opportunities in life sciences. The event will take place October 7-8, 2014 at the Palace Hotel in San Francisco, California. 

“Over the past three years, more than 30 of the private companies that presented at a BIO Investor Forum have gone public, generating a current combined market capitalization of nearly $15 billion,” said Jim Greenwood, CEO and President at BIO. “Investors are eager to learn about and evaluate fresh new investment opportunities, as evidenced by the 30% increase in investor registration to date compared to last year.”

Presenting companies have a clear R&D focus with a pipeline involving biotechnology for therapeutics, diagnostics or platform technologies. More than one-quarter of the public presenting companies at the event have gone public since passage of the Jumpstart Our Business Startups (JOBS) Act in April 2012. To date, overall, 111 biotech companies have gone public since passage of the JOBS Act.

New presenting companies are continuously being added. For updates on the list of presenters, please visit here. If you are interested in becoming a presenter, please submit an application here.

The following companies will present at the 13th Annual BIO Investor Forum:

Private:

AbGenomics International

Actogenix NV

Adaptimmune

Aduro Biotech

BEAT BioTherapeutics

Berg

Blueprint Medicines

Cebix, Inc.

Cerecor

CoLucid Pharmaceuticals

Critical Outcome Technologies Inc.

CytomX Therapeutics

Ennaid Therapeutics

Evgen Pharma

Genkyotex SA

Immatics Biotechnologies

ImmunGene

INHIBRx

Isarna Therapeutics

Juventas Therapeutics

Kadmon Corporation

KineMed

Maverix Bomics

MAX BioPharma

MiNA Therapeutics

Mirna Therapeutics

Neumedicines Inc.

NuvOx Pharma

Oryzon

Oxyrane

PaxVax

Polynoma

Protagonist Therapeutics, Inc.

Provista Diagnostics

Sutro Biopharma

Targazyme

Theravectys

Vascular Pharmaceuticals

VivaBioCell

Vivaldi Biosciences Inc.

 

Public:

Apricus Bioscience

Arno Therapeutics

Benitec

Biocept*

Bio-Path Holdings

CareDx*

Catalyst Pharmaceutical Partners

Celladon Corporation*

ContraFect Corporation*

Critical Outcome Technologies

CymaBay Therapeutics

Dicerna Pharmaceuticals*

GlobeImmune*

GlycoMimetics*

Heat Biologics

Horizon Pharma

Immunovaccine Inc.

Innovus Pharma

Lpath Inc.

Mast Therapeutics

Matinas BioPharma

NeoStem

NephroGenex*

Newron Pharmaceuticals SpA

NovaBay Pharmaceuticals

Ocera Inc.

OncoMed Pharmaceuticals*

OncoSec Medical

Palatin Technologies

Pfenex*

Radius Health*

Regulus*

Relypsa*

Resverlogix

Rexahn Pharmaceuticals

RXi Pharmaceuticals

TherapeuticsMD

Trovagene, Inc.

TxCell SA

*Denotes companies who went public since passage of the JOBS Act

Now a staple at the BIO Investor Forum, the event will again host a series of Discovery Track presentations that feature Seed and A-round companies incorporated after 2009 and have raised less than $25M through October 2014. Companies in this track are also first-time presenters and use biotechnology or related technologies for research and development of drug products or diagnostics. The following companies are scheduled to present in the Discovery Track:

Aeglea BioTherapeutics

Allinky Biopharma

Atterocor

Bell Biosystems

BioKier

Bioniz LLC

BioNovion B.V.

Biscayne Pharmaceuticals

CompuVax

Corbus Pharmaceuticals

EternoGen

ETX Pharma, Inc.

GrayBug LLC

Humanetics Corp.

Makindus Inc.

MentiNova, Inc.

OncoSynergy

Recursion Pharmaceuticals

Relburn-Metabolomics Inc.

Stemsynergy Therapeutics

Sulfagenix

Tunitas Therapeutics

Tute Genomics

Also presenting in the Discovery Track will be several patient advocacy groups looking for potential research partners:

Juvenile Diabetes Research Foundation

Rare Cancer Research Foundation

New to BIO Investor Forum this year, the Buzz of BIO contest is recognizing “Early Stage Entrepreneurs” and “Late Stage Leaders.” One winner from each category will receive complimentary registration and a company presentation opportunity.  Voting opens today, August 25, and winners will be selected by number of votes, on September 4, 2014. Nominees include:

Early Stage Entrepreneur:

Bell Biosystems

BioAegis Therapeutics

BNOAT Oncology

Inhibrx LLC

NanoSomiX Inc.

NVIGEN Inc.

RoosterBio

Synergys Biotherapeutics

Targeson, Inc.

Xcell Biosciences

Late Stage Leader:

Avedro Inc.

CorMatrix Cardiovascular

Enable Injections, LLC

Forsight Vision5

Hemoshear

KineMed, Inc.

Tobira Therapeutics

Trevi Therapeutics

To learn more about the BIO Investor Forum, including registration, program and partnering information, please visit here. Media registration is now open for qualified members of the press.

About BIO
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.